Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges (2014 - 2026)
Ani Pharmaceuticals (ANIP) posted Amortization of Deferred Charges of $358000.0 for Q1 2026, down 35.5% sequentially from $555000.0 in Q4 2025, and up 10.49% YoY from $324000.0 in Q1 2025.
Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Amortization of Deferred Charges for 13 years, with the latest figure at $358000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 10.49% year-over-year to $358000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 19.04% YoY) and the FY2025 annual result came in at $1.8 million, up 15.27% from the prior year.
- Amortization of Deferred Charges fell to $358000.0 in Q1 2026 per ANIP's latest filing, from $555000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $3.9 million in Q4 2023 and troughed at $300000.0 in Q3 2024.
- A 5-year average of $770466.7 and a median of $555000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2022 and 2024: Amortization of Deferred Charges jumped 71.68% in 2022, then plunged 90.01% in 2024.
- Over 5 years, Amortization of Deferred Charges stood at $592000.0 in 2022, then jumped by 562.5% to $3.9 million in 2023, then plunged by 90.01% to $392000.0 in 2024, then soared by 41.58% to $555000.0 in 2025, then slumped by 35.5% to $358000.0 in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $358000.0, $555000.0, and $500000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.28 Bn | 165.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 854,000.00 |
| Jun 30, 2026 | 854,000.00 |
| Mar 31, 2026 | 358,000.00 |
| Mar 31, 2026 | 358,000.00 |
| Dec 31, 2025 | 555,000.00 |
| Dec 31, 2025 | 555,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 324,000.00 |
| Mar 31, 2025 | 324,000.00 |
| Dec 31, 2024 | 392,000.00 |
| Dec 31, 2024 | 392,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 591,000.00 |
| Jun 30, 2024 | 591,000.00 |
| Mar 31, 2024 | 373,000.00 |
| Mar 31, 2024 | 373,000.00 |